solid tumour
Conditions
Brief summary
Modification(s) in the immune blood markers including serum autoantibody level of treated subjects at three different time points during the treatment by ICI (early, mid time and late) and at the occurrence of irAEs as described below compared to baseline. Safety will be assessed: by the investigator(s) by using the adverse events reported during the study in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Interventions
DRUGATEZOLIZUMAB
DRUGDURVALUMAB
DRUGAVELUMAB
DRUGOXALIPLATIN
DRUGIPILIMUMAB
DRUGAXITINIB
DRUGsolution à diluer pour perfusion
DRUGAbraxane 5 mg/ml powder for dispersion for infusion.
DRUGPEGFILGRASTIM
DRUGCETIRIZINE
DRUGFLUOROURACIL
DRUGCABOZANTINIB
DRUGPEMBROLIZUMAB
DRUGPACLITAXEL
DRUGNIVOLUMAB
DRUGPEMETREXED
DRUGETOPOSIDE
DRUGALIZAPRIDE
DRUGCISPLATIN
DRUGDEXAMETHASONE SODIUM PHOSPHATE
DRUGBEVACIZUMAB
DRUGCALCIUM FOLINATE
DRUGCEMIPLIMAB
Sponsors
Institut Jules Bordet
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modification(s) in the immune blood markers including serum autoantibody level of treated subjects at three different time points during the treatment by ICI (early, mid time and late) and at the occurrence of irAEs as described below compared to baseline. Safety will be assessed: by the investigator(s) by using the adverse events reported during the study in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. | — |
Countries
Belgium
Outcome results
None listed